TrialBlood2014

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.

Jesús San-Miguel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.